208 related articles for article (PubMed ID: 27521731)
1. Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma.
Eli IM; Raheja A; Corn HJ; Simmons DL; Palmer CA; Couldwell WT
World Neurosurg; 2016 Nov; 95():622.e1-622.e5. PubMed ID: 27521731
[TBL] [Abstract][Full Text] [Related]
2. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
Yano S; Hide T; Uekawa K; Honda Y; Mikami Y; Kuratsu JI
World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
[TBL] [Abstract][Full Text] [Related]
3. Prolactinoma in a Dog.
Cosio C; Sartori E; Garatti M; Luccardini L; Grinwis GCM; Kooistra HS; Fracassi F
Vet Pathol; 2017 Nov; 54(6):972-976. PubMed ID: 28812531
[TBL] [Abstract][Full Text] [Related]
4. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
5. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation.
Levine SN; Ishaq S; Nanda A; Wilson JD; Gonzalez-Toledo E
Ann Diagn Pathol; 2013 Aug; 17(4):361-6. PubMed ID: 23602507
[TBL] [Abstract][Full Text] [Related]
7. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
[TBL] [Abstract][Full Text] [Related]
8. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
[TBL] [Abstract][Full Text] [Related]
9. Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.
van Uum SH; van Alfen N; Wesseling P; van Lindert E; Pieters GF; Nooijen P; Hermus AR
J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1489-91. PubMed ID: 15377706
[TBL] [Abstract][Full Text] [Related]
10. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
[TBL] [Abstract][Full Text] [Related]
11. Sellar Toxoplasmosis and Nonfunctioning Pituitary Adenoma.
Berkmann S; Fischer I; Sonderegger B; Fischli S; Fandino J
World Neurosurg; 2015 Nov; 84(5):1495.e1-4. PubMed ID: 26026632
[TBL] [Abstract][Full Text] [Related]
12. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
Krassas GE; Pontikides N; Kaltsas T
Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
[TBL] [Abstract][Full Text] [Related]
13. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
14. Persistence of intrasellar trigeminal artery and simultaneous pituitary adenoma: description of two cases and their importance for the differential diagnosis of sellar lesions.
Machado MC; Kodaira S; Musolino NR
Arq Bras Endocrinol Metabol; 2014 Aug; 58(6):661-5. PubMed ID: 25211451
[TBL] [Abstract][Full Text] [Related]
15. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
Mallea-Gil MS; Cristina C; Perez-Millan MI; Villafañe AM; Ballarino C; Stalldecker G; Becu-Villalobos D
Endocr Pathol; 2009; 20(1):35-40. PubMed ID: 19172414
[TBL] [Abstract][Full Text] [Related]
16. [Hyperprolactinemia: unusual association between peripheral hypothyroidism and microprolactinoma].
Chafik A; El Mghari G; El Ansari N
Pan Afr Med J; 2016; 24():41. PubMed ID: 27642382
[TBL] [Abstract][Full Text] [Related]
17. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
[TBL] [Abstract][Full Text] [Related]
18. [Prolactin-secreting microadenoma in menopausal women].
Barka I; Dendana E; Chikhrouhou N; Maroufi A; Kacem M; Chadli M; Ach K
Pan Afr Med J; 2017; 27():177. PubMed ID: 28904704
[TBL] [Abstract][Full Text] [Related]
19. Long-term radiographic follow-up of the sella turcica in hyperprolactinaemic women.
Rasmussen C; Larsson SG; Bergh T
Aust N Z J Obstet Gynaecol; 1990 Aug; 30(3):257-64. PubMed ID: 2256866
[TBL] [Abstract][Full Text] [Related]
20. Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now?
Christoforidis A; Tsakalides C; Anastasiou A; Pavlaki A; Dimitriadou M
Neuro Endocrinol Lett; 2013; 34(4):275-7. PubMed ID: 23803868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
